Quantcast
Last updated on April 17, 2014 at 11:47 EDT

Latest PLK1 Stories

2013-04-10 16:05:38

Study of RNA interference drug presented at AACR Annual Meeting 2013 The safety and preliminary efficacy of a new class of tumor fighting drugs were reported today by Scottsdale Healthcare's Virginia G. Piper Cancer Center Clinical Trials and the Translational Genomics Research Institute (TGen). Early results from the phase I, first in-human study of an RNA interference (RNAi) drug were announced during the American Association for Cancer Research (AACR) Annual Meeting 2013, April 6-10,...

2013-03-13 18:06:19

A better 'mousetrap' discovered in fruit flies might stop a human cancer-driving kinase in its tracks A seemingly obscure gene in the female fruit fly that is only active in cells that will become eggs has led researchers at the Stowers Institute for Medical Research to the discovery of a atypical protein that lures, traps, and inactivates the powerful Polo kinase, widely considered the master regulator of cell division. Its human homolog, Polo-like kinase-1 (Plk1), is misregulated in many...

2012-04-18 10:25:01

Combination of antibody fragment and packaging peptide addresses siRNAs to breast tumor cells BOSTON, Mass., April 18, 2012 /PRNewswire-USNewswire/ -- Researchers in the Program in Cellular and Molecular Medicine at Boston Children's Hospital and the Immune Disease Institute (PCMM/IDI) have developed a molecular delivery platform that overcomes one of the biggest obstacles to using RNA-based gene silencing technologies to treat cancer: Making sure the treatment gets to the right...

2012-03-02 13:43:15

The American Cancer Society estimates that 44,000 new cases of pancreatic cancer will be diagnosed this year and that 37,000 people will die from the disease. These are not strong odds. A new drug, rigosertib, allows pancreatic cancer cells to rush through replication — and then stops them cold, killing them in in the middle of a step called M phase. Healthy cells that don´t rush are unharmed. Data from a phase I clinical trial of patients with advanced pancreatic cancer and...

2011-12-29 14:41:00

GRAND RAPIDS, Mich., Dec. 29, 2011 /PRNewswire/ -- Two recent studies by Van Andel Research Institute scientists are providing a foundation for a more complete understanding of distinct kidney cancer subtypes, which could pave the way for better treatments. In a study published in Cancer Cell led by Kyle Furge, Ph.D. and Aikseng Ooi, Ph.D., researchers provide a more complete understanding of the biology of Type 2 papillary renal cell carcinoma (PRCC2), an...

2011-09-28 14:47:26

Purdue University scientists believe they have found an effective target for killing late-stage, metastatic prostate cancer cells. Xiaoqi Liu, an assistant professor of biochemistry and member of Purdue's Center for Cancer Research, and graduate student Shawn Liu are focusing on the function of a gene called Polo-like kinase (Plk1), a critical regulator of the cell cycle. Plk1 is also an oncogene, which tends to mutate and can cause cancer. The researchers found that later-stage...

2011-07-19 15:49:06

Researchers are able to precisely simulate the inhibition of genes with new cancer drugs Only one in twenty cancer drugs makes its way from the laboratory to become an approved pharmaceutical product. The majority of new agents are only shown to be unsuitable in the later phases of clinical development which would explain the exorbitantly high development costs of 500 to 600 million euros per new cancer drug. In order to recognize at an earlier stage which side effects are associated with the...

2011-01-12 07:00:00

Clinical study open at Virginia G. Piper Cancer Center at Scottsdale Healthcare SCOTTSDALE, Ariz., Jan. 12, 2011 /PRNewswire-USNewswire/ -- A new investigational drug designed to stop cancer cells from reproducing may offer hope for patients with advanced solid tumor cancers. Clinical trials of TKM-PLK1 for qualified patients are now open at the Virginia G. Piper Cancer Center at Scottsdale Healthcare. TKM-PLK1 targets a protein called polo-like kinase 1 (PLK1) that promotes tumor cell...

2009-12-08 19:37:56

NMS-1286937 is designed to halt cancer cells from dividing TGen Clinical Research Services at Scottsdale Healthcare (TCRS) is the world's first clinical trials site for a new drug designed to halt cancer cell division. NMS-1286937 is produced by Nerviano Medical Sciences of Milan, Italy's largest pharmaceutical research and development facility. NMS-1286937 is designed to stop cancer from spreading by preventing mitosis, the process of cell division. "Cancer is driven by abnormal cell...

2009-07-07 16:06:24

A Purdue University scientist has discovered a key process in cell growth that can lead to the formation of tumors.Xiaoqi Liu, an assistant professor of biochemistry, found that an overabundance of the polo-like kinase 1, or Plk1, molecule during cell growth, as well as a shortage of the p53 molecule, will lead to tumor formation. Studies in Liu's laboratory showed that the Plk1 molecule indirectly attacks p53 in a process called ubiquitination."This provides the mechanism for how p53 loses...